PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute
·
The National Cancer Institute's (NCI) Phase II clinical study of PDS Biotech's PDS0101 for HPV-associated cancers has achieved its preliminary objective response.
·
Full enrollment for the Phase II trial is triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients
·
Milestone for
treatment of
HPV-associated cancers
NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces
that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) has achieved its preliminary objective response for the National Cancer Institute's (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment.